Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells.
Baumeister J, Maié T, Chatain N, Gan L, Weinbergerova B, de Toledo MAS, Eschweiler J, Maurer A, Mayer J, Kubesova B, Racil Z, Schuppert A, Costa I, Koschmieder S, Brümmendorf TH, Gezer D. Baumeister J, et al. Among authors: gezer d. Ann Hematol. 2021 Dec;100(12):2943-2956. doi: 10.1007/s00277-021-04615-8. Epub 2021 Aug 14. Ann Hematol. 2021. PMID: 34390367 Free PMC article.
Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.
Isfort S, Crysandt M, Gezer D, Koschmieder S, Brümmendorf TH, Wolf D. Isfort S, et al. Among authors: gezer d. Recent Results Cancer Res. 2018;212:87-108. doi: 10.1007/978-3-319-91439-8_4. Recent Results Cancer Res. 2018. PMID: 30069626
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.
Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maié T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brümmendorf TH, Müller-Newen G, Mayer J, Racil Z, Kubesova B, Knudsen T, Sørensen AL, Holmström M, Kjær L, Skov V, Larsen TS, Hasselbalch HC, Chatain N, Koschmieder S. Czech J, et al. Among authors: gezer d. Leukemia. 2019 Apr;33(4):995-1010. doi: 10.1038/s41375-018-0295-6. Epub 2018 Nov 23. Leukemia. 2019. PMID: 30470838
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.
Rao TN, Hansen N, Hilfiker J, Rai S, Majewska JM, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW, Lane AN, Handschin C, Dirnhofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić VP, Skoda RC. Rao TN, et al. Among authors: gezer d. Blood. 2019 Nov 21;134(21):1832-1846. doi: 10.1182/blood.2019000162. Blood. 2019. PMID: 31511238 Free PMC article.
Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms.
Baumeister J, Chatain N, Hubrich A, Maié T, Costa IG, Denecke B, Han L, Küstermann C, Sontag S, Seré K, Strathmann K, Zenke M, Schuppert A, Brümmendorf TH, Kranc KR, Koschmieder S, Gezer D. Baumeister J, et al. Among authors: gezer d. Leukemia. 2020 Apr;34(4):1062-1074. doi: 10.1038/s41375-019-0629-z. Epub 2019 Nov 14. Leukemia. 2020. PMID: 31728053
CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes.
Olschok K, Han L, de Toledo MAS, Böhnke J, Graßhoff M, Costa IG, Theocharides A, Maurer A, Schüler HM, Buhl EM, Pannen K, Baumeister J, Kalmer M, Gupta S, Boor P, Gezer D, Brümmendorf TH, Zenke M, Chatain N, Koschmieder S. Olschok K, et al. Among authors: gezer d. Stem Cell Reports. 2021 Nov 9;16(11):2768-2783. doi: 10.1016/j.stemcr.2021.09.019. Epub 2021 Oct 21. Stem Cell Reports. 2021. PMID: 34678208 Free PMC article.
35 results